Boardroom Alpha
Boardroom Alpha
CME · Current Report (Form 8-K) · Filed May 19, 2026

Cme Group Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 19, 2026
Period
May 14, 2026
Ticker
CME
Accession
0001156375-26-000028
Boardroom Alpha · Filing insights

Class B quorum failed; meeting adjourned to June 9, 2026; equity directors elected and major votes ratified.

About Cme Group Inc
Market cap
$90.8B
1Y TSR
+7.7%
3Y TSR
+21.1%
Board grade
B-
Sector
Financial Services
CEO
Terrence A Duffy
Last annual meeting: May 14, 2026 · View full Cme Group Inc profile →
cme-20260514

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
_________________________________________________________
FORM 8-K
 
_________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) May 18, 2026 (May 14, 2026)
 
 _________________________________________________________
CME GROUP INC.
(Exact Name of Registrant as Specified in its Charter) 
_________________________________________________________ 
Delaware 001-31553 36-4459170
(State or Other Jurisdiction
of Incorporation)
 (Commission
File No.)
 (IRS Employer
Identification No.)
 
20 South Wacker DriveChicagoIllinois 60606
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (312) 930-1000
N/A
(Former Name or Former Address, if Changed Since Last Report) 
______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Class A Common StockCMENasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 5.07. Submission of Matters to a Vote of Security Holders.

CME Group Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders on May 14, 2026 (the “Annual Meeting”). At the close of business on March 16, 2026, the record date of the Annual Meeting, the Company had 362,808,081 shares of Class A and Class B common stock issued and outstanding. The following shares were present at the Annual Meeting, either in person or by proxy.

Class(es) of Common Stock
Aggregate No. of Shares
% of the Issued and Outstanding
Classes A and B
318,466,54487.78 %
Class B-1
20733.12 %
Class B-2
25531.37 %
Class B-3
31124.16 %
Class B-4
10525.42 %

For each class of common stock, at least 33.3% of the common stock issued and outstanding must be present at the Annual Meeting to obtain quorum. Accordingly, Class B-1, Class B-2, Class B-3 and Class B-4 did not reach quorum. In light of the low participation from the Class B shareholders at the Annual Meeting, the proposals presented under Items 4 through 8 were adjourned to a meeting to be held virtually on June 9, 2026 at 11:00 a.m. Central Time.

The results of the proposals that were voted on at the Annual Meeting, which are described in further detail in the Company's definitive proxy statement on Schedule 14A filed with the SEC on March 23, 2026, are as follows:

1.Each of the Equity Director nominees were elected to serve until the 2027 annual meeting of shareholders based on the following votes. For this item, Class A and Class B shareholders vote together as a single class. There were a total of 23,505,825 broker non-votes in this proposal.
Equity DirectorsFORAGAINSTABSTAIN
Terrence A. Duffy267,885,38626,615,419459,914
Kathryn Benesh286,032,0478,324,133604,539
Timothy S. Bitsberger267,913,18826,461,432586,099
Charles P. Carey252,305,37041,546,8961,108,453
Bryan T. Durkin280,480,50813,830,690649,521
Harold Ford Jr.285,672,9598,650,548637,212
Martin J. Gepsman242,151,52552,090,523718,671
Daniel G. Kaye281,023,71713,356,331580,671
Phyllis M. Lockett258,393,13935,557,4921,010,088
Deborah J. Lucas286,008,9828,354,274597,463
Rahael Seifu271,627,73722,563,896769,086
William R. Shepard268,926,95425,612,160421,605
Howard J. Siegel273,255,55421,183,226521,939
Dennis A. Suskind257,757,95436,335,165867,600








2.The proposal to ratify the appointment of Ernst & Young LLP as the Company's independent auditor for 2026 was approved based upon the following votes. For this item, Class A and Class B shareholders vote together as a single class.

FORAGAINSTABSTAIN
291,376,90526,595,015494,624


3.The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers was approved based upon the following votes. For this item, Class A and Class B shareholders vote together as a single class. There were a total of 23,505,825 broker non-votes for this proposal.

FORAGAINSTABSTAIN
259,576,11234,530,288854,319









SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 CME Group Inc.
 Registrant
Date: May 19, 2026 By: /s/ Jonathan Marcus
 Name:
Title:
 
Jonathan Marcus
Senior Managing Director and
General Counsel


  








From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cme Group Inc (CME)

Reference

Frequently asked questions

When did Cme Group Inc file this 8-K?
Cme Group Inc (CME) filed this Current Report (Form 8-K) with the SEC on May 19, 2026. The accession number assigned by EDGAR is 0001156375-26-000028.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Class B quorum failed; meeting adjourned to June 9, 2026; equity directors elected and major votes ratified. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Cme Group Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Cme Group Inc has filed under CIK 1156375, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer